EA200300027A1 - Способ лечения сердечно-сосудистых заболеваний - Google Patents

Способ лечения сердечно-сосудистых заболеваний

Info

Publication number
EA200300027A1
EA200300027A1 EA200300027A EA200300027A EA200300027A1 EA 200300027 A1 EA200300027 A1 EA 200300027A1 EA 200300027 A EA200300027 A EA 200300027A EA 200300027 A EA200300027 A EA 200300027A EA 200300027 A1 EA200300027 A1 EA 200300027A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cardiovascular diseases
treating cardiovascular
mammal
vascular disease
disease
Prior art date
Application number
EA200300027A
Other languages
English (en)
Inventor
Нил Иван Азролан
Сурендра Нэт Сейгал
Стивен Джей Эйдэлман
Original Assignee
Уайт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22789625&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200300027(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Уайт filed Critical Уайт
Publication of EA200300027A1 publication Critical patent/EA200300027A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к способу лечения или профилактики заболевания сердечно-сосудистой системы, заболевания мозговых сосудов или заболевания периферических сосудов у млекопитающего, нуждающегося в этом, который включает в себя обеспечение указанному млекопитающему эффективного количества рапамицина.Отчет о международном поиске был опубликован 2002.05.10.
EA200300027A 2000-06-16 2001-06-14 Способ лечения сердечно-сосудистых заболеваний EA200300027A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21211700P 2000-06-16 2000-06-16
PCT/US2001/019179 WO2001097809A2 (en) 2000-06-16 2001-06-14 Method of treating cardiovascular disease using rapamycin

Publications (1)

Publication Number Publication Date
EA200300027A1 true EA200300027A1 (ru) 2003-06-26

Family

ID=22789625

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300027A EA200300027A1 (ru) 2000-06-16 2001-06-14 Способ лечения сердечно-сосудистых заболеваний

Country Status (19)

Country Link
US (1) US20020013335A1 (ru)
EP (1) EP1292302A2 (ru)
JP (1) JP2003535899A (ru)
KR (1) KR20030010710A (ru)
CN (1) CN1436076A (ru)
AR (1) AR028959A1 (ru)
AU (2) AU6844601A (ru)
BR (1) BR0111601A (ru)
CA (1) CA2412636A1 (ru)
CZ (1) CZ20024115A3 (ru)
EA (1) EA200300027A1 (ru)
HU (1) HUP0301244A3 (ru)
IL (1) IL153405A0 (ru)
MX (1) MXPA02012410A (ru)
NO (1) NO20026008L (ru)
NZ (1) NZ523114A (ru)
PL (1) PL365455A1 (ru)
WO (1) WO2001097809A2 (ru)
ZA (1) ZA200300418B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269603B1 (en) 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
PL216224B1 (pl) 2002-02-01 2014-03-31 Ariad Pharmaceuticals Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
DK1553940T3 (da) * 2002-07-30 2008-06-02 Wyeth Corp Patenterale formuleringer indeholdende en rapamycin-hydroxyester
CN100415233C (zh) * 2002-09-17 2008-09-03 惠氏公司 口服制剂
WO2004060283A2 (en) 2002-12-16 2004-07-22 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AR042938A1 (es) 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US7728033B2 (en) 2003-05-05 2010-06-01 Clinigene International Private Limited Mycophenolate mofetil in diabetic nephropathy
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
DE102004019845A1 (de) * 2004-03-29 2005-10-20 Krka Tovarna Zdravil D D Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung
US20050232965A1 (en) * 2004-04-15 2005-10-20 Robert Falotico Local administration of a combination of rapamycin and 17 beta-estradiol for the treatment of vulnerable plaque
DE602005025755D1 (de) * 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
CN100435755C (zh) * 2004-07-27 2008-11-26 微创医疗器械(上海)有限公司 药物洗脱支架
EP1656941A1 (en) * 2004-11-09 2006-05-17 Clinigene International Private Limited Compositions for the treatment of diabetic nephropathy
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
CN100384416C (zh) * 2006-03-20 2008-04-30 杨军 一种用于治疗心血管疾病的药物组合物
US8414909B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
JP5746749B2 (ja) 2010-03-15 2015-07-08 エクソンモービル・ケミカル・パテンツ・インク アルコールの製造方法
US20150290176A1 (en) * 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
US10098871B2 (en) * 2013-03-15 2018-10-16 Leslie B. Gordon Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
CN105997940A (zh) * 2016-05-11 2016-10-12 中国人民解放军第三军医大学 炎症微环境响应性纳米药物、其制备方法及应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
PL337320A1 (en) * 1997-06-13 2000-08-14 American Home Prod Rapamycin preparations for oral administration
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin

Also Published As

Publication number Publication date
WO2001097809A3 (en) 2002-05-10
NO20026008D0 (no) 2002-12-13
MXPA02012410A (es) 2003-04-25
CA2412636A1 (en) 2001-12-27
CN1436076A (zh) 2003-08-13
AU6844601A (en) 2002-01-02
BR0111601A (pt) 2003-07-01
PL365455A1 (en) 2005-01-10
AR028959A1 (es) 2003-05-28
HUP0301244A3 (en) 2005-01-28
WO2001097809A2 (en) 2001-12-27
NZ523114A (en) 2004-07-30
ZA200300418B (en) 2004-04-15
EP1292302A2 (en) 2003-03-19
AU2001268446B2 (en) 2005-08-11
HUP0301244A2 (hu) 2003-08-28
KR20030010710A (ko) 2003-02-05
NO20026008L (no) 2002-12-13
IL153405A0 (en) 2003-07-06
US20020013335A1 (en) 2002-01-31
JP2003535899A (ja) 2003-12-02
CZ20024115A3 (cs) 2003-06-18

Similar Documents

Publication Publication Date Title
EA200300027A1 (ru) Способ лечения сердечно-сосудистых заболеваний
BRPI0307673A2 (pt) métodos de tratar doença vascular.
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
EA200300387A1 (ru) Ингибиторы рецептора ep4 для лечения ревматоидного артрита
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
MA26782A1 (fr) Pyrazolobenzodiazepines en tant qu'inhibiteurs de cdk2.
HK1070575A1 (en) Use of botulinum toxin for treating cardiovasculardiseases
BR0211905A (pt) Dialdeìdos de rapamicina
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
ATE286895T1 (de) Sulfonyl-pyrrolidinderivate geeignet für die behandlung von neurologischen krankheiten
WO2002059346A3 (en) Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents
DE60025639D1 (de) Substituierte diazepan
WO2002039122A3 (en) Methods for the identification and the treatment of cardiovascular disease
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
EP1254260A4 (en) METHODS FOR DIAGNOSING AND TREATING A HEART DISEASE
EA200100930A1 (ru) Способ лечения хозл
DE60000639D1 (de) Verbesserter Monitor für Sportstadium
WO2001087239A3 (en) Methods of affecting laminin 5 processing
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
DE60112768D1 (de) Behandlung von entzündlichen erkrankungen
EA200000740A1 (ru) Способ лечения заболевания хронической закупорки легочных путей
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.